Source: Annual Congress 2011 - COPD exacerbation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. P. M. H. Rutten-van Mölken, L. M. Fabbri, K. F. Rabe, H. Kögler, T. Glaab, H. Schmidt, K. M. Beeh, C. Vogelmeier (Rotterdam, Netherlands; Modena, Italy; Grosshansdorf, Ingelheim, Wiesbaden, Marburg, Germany). Do exacerbation outcomes in the POET-COPDÔ trial differ between regions?. Eur Respir J 2011; 38: Suppl. 55, 559

Member's Comments

No comment yet.

Related content which might interest you: Are there patient characteristics associated with improvements or worsening in the placebo arm of COPD tlinical trials? Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Who win? Spirometry versus symptoms for predicting the longitudinal outcomes in COPD patients – 10 years observation Source: Annual Congress 2011 - Clinical parameters in airway diseases Year: 2011 Effects of case management on hospitalisation and exacerbation rate in severe, complex COPD: A randomized controlled trial Source: Annual Congress 2011 - Exacerbations and severe chronic respiratory disease: oxygen, rehabilitation, admission to hospital and palliative care Year: 2011 Patients’ adherence to treatment: How does it changes in 1 year after finishing of the participation in trial? Source: Annual Congress 2013 –New treatments and old dilemmas in the clinical management of lung diseases Year: 2013 Does excluding subjects with features similar to IPF affect the results of the INBUILD trial of nintedanib? Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Impact of community pharmacists‘ interventions on patients‘ asthma control and perception of therapy and disease: Results in patients with inadequate control at inclusion Source: Annual Congress 2010 - Therapy and health economics of asthma and COPD Year: 2010 COPD phenotypes and co-morbidities: to what extent do they affect a successful response to rehabilitation? Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD Year: 2011 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Real-life COPD patients compared to large trial populations: An UNLOCK external validity study Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Does SpO2 correlate with SaO2 in stable COPD patients? Source: Annual Congress 2012 - Various issues in clinical physiology Year: 2012 LATE-BREAKING ABSTRACT: Treating the most diseased segments in patients with severe emphysema: 6 month results from the STEP-UP randomized controlled trial (RCT) Source: International Congress 2015 – Advances in therapeutic bronchoscopy Year: 2015 Assessing quality of care from the patients‘ and parent‘s perspective in three paediatric asthma settings; a randomised controlled study in children with stable asthma Source: Annual Congress 2011 - Coping and lifestyle in childhood asthma Year: 2011 Changes of quality of life after short rehabilitation treatment in COPD patients: comparison between three groups of different age Source: Eur Respir J 2006; 28: Suppl. 50, 556s Year: 2006 Cxr interpretation in patients presenting with an acute infective exacerbation of COPD: comparison between clinicians‘ and radiologists‘ interpretations and implications on clinical decision and management Source: Annual Congress 2009 - Imaging of COPD, asthma and emphysema in evolution Year: 2009 Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Does a predominant clinical COPD phenotype predict different outcome responses to pulmonary rehabilitation? Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care Year: 2012